Anne Wojcicki’s nonprofit wins bid to acquire genetic testing company 23andMe

TTAM Research Institute, a nonprofit led by 23andMe co-founder Anne Wojcicki, has won the bid to acquire the bankrupt genetic testing company for $305 million, surpassing Regeneron Pharmaceuticals' earlier offer of $256 million. The acquisition, which includes 23andMe's personal genome service and Lemonaid Health, follows a period of internal turmoil, including mass director resignations and workforce reductions, and raises concerns about the privacy of genetic data collected from 15 million customers; a lawsuit has been filed by 27 states and D.C. to prevent the sale of this data without consent.

Analysis

TTAM Research Institute, a nonprofit led by 23andMe co-founder Anne Wojcicki, has secured the acquisition of the bankrupt genetic testing company for $305 million, a figure surpassing Regeneron Pharmaceuticals' $256 million offer. This transaction marks a dramatic decline for 23andMe, once valued at $6 billion, which filed for Chapter 11 bankruptcy in March following severe operational and governance crises. These included the en masse resignation of all seven independent directors in September 2024, attributed to frustrations with Wojcicki’s strategic direction and efforts to take the company private, followed by a 40% workforce reduction in November 2024. The company's substantial database, containing genetic information from 15 million customers, is now at the center of significant data privacy concerns, highlighted by a lawsuit from 27 states and the District of Columbia seeking to block the sale of this data without explicit customer consent. Regeneron Pharmaceuticals cited "its assessment of 23andMe’s remaining value" for not submitting a higher bid, reflecting the perceived distress and risk associated with the assets. Despite the extremely negative sentiment (-0.8) and uncertain outlook surrounding 23andMe's demise, TTAM Research Institute—an acronym for "the first letters of 23andMe"—has pledged to comply with existing privacy policies and honor customer data rights for the acquired assets, which include the personal genome service, research services, and Lemonaid Health. The acquisition remains subject to approval by the US Bankruptcy Court for the Eastern District of Missouri, with a hearing scheduled for June 17.

Key Decisions for Investors

• Investors should interpret the $305 million acquisition price for 23andMe, a steep discount from its peak $6 billion valuation, as a critical data point on the valuation and monetization challenges within the consumer genomics sector, particularly in light of substantial data privacy liabilities and regulatory pressures.
• For Regeneron Pharmaceuticals (REGN) investors, the decision not to pursue a higher bid based on its internal valuation underscores a potentially disciplined capital allocation strategy, choosing to avoid overpaying for highly distressed assets burdened with significant legal and operational uncertainties.
• The prominent multi-state lawsuit and TTAM Research Institute's explicit commitments to uphold privacy standards emphasize the escalating regulatory and reputational risks tied to consumer genetic data, which should be a primary diligence factor for investments across the healthcare data and personalized medicine landscape.